{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T08:25:49Z","timestamp":1794644749029,"version":"4.9.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1007\/s00198-011-1791-y","type":"journal-article","created":{"date-parts":[[2011,9,26]],"date-time":"2011-09-26T12:26:44Z","timestamp":1317040004000},"page":"267-276","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy and safety of a novel delayed-release risedronate 35\u00a0mg once-a-week tablet"],"prefix":"10.1007","volume":"23","author":[{"given":"M. R.","family":"McClung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zanchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. A.","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Benhamou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Balske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. E.","family":"Burgio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Sarley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. K.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. R.","family":"Recker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,9,27]]},"reference":[{"key":"1791_CR1","unstructured":"Merck & Co., Inc. Fosamax\u00ae Prescribing Information. http:\/\/www.merck.com\/product\/usa\/pi_circulars\/f\/fosamax\/fosamax_pi.pdf . Accessed 18 March 2011"},{"key":"1791_CR2","unstructured":"Warner Chilcott. Actonel\u00ae Prescribing Information. http:\/\/actonel.com\/global\/prescribing_information.pdf . Accessed 18 March 2011"},{"key":"1791_CR3","unstructured":"Roche Therapeutics, Inc. Boniva\u00ae Prescribing Information. http:\/\/www.rocheusa.com\/products\/Boniva\/PI.pdf . Accessed 18 March 2011"},{"issue":"5","key":"1791_CR4","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","volume":"4","author":"B Ettinger","year":"1998","unstructured":"Ettinger B, Pressman A, Schein J, Chan J, Silver P, Connolly N (1998) Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Manag Care Pharm 4(5):488\u2013492","journal-title":"J Manag Care Pharm"},{"key":"1791_CR5","doi-asserted-by":"crossref","unstructured":"Fleisch H (2000) Pharmacokinetics. In: Bisphosphonates in bone disease: from the laboratory to the patient. 4th ed. San Diego: Academic. p. 56\u201362","DOI":"10.1016\/B978-012260371-6\/50005-7"},{"key":"1791_CR6","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/0091270004267594","volume":"44","author":"J Barrett","year":"2004","unstructured":"Barrett J, Worth E, Bauss F, Epstein S (2004) Ibandronate: a clinical pharmacological and pharmacokinetic update. J Clin Pharmacol 44:951\u2013965","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"1791_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s00774-003-0459-x","volume":"22","author":"Y Ogura","year":"2004","unstructured":"Ogura Y, Gohsho A, Cyong J-C, Orimo H (2004) Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption. J Bone Miner Metab 22(2):120\u2013126","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"1791_CR8","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1532-5415.2006.00696.x","volume":"54","author":"S Agrawal","year":"2006","unstructured":"Agrawal S, Krueger DC, Engelke JA et al (2006) Between-meal risedronate does not alter bone turnover in nursing home residents. J Am Geriatr Soc 54(5):790\u2013795","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"1791_CR9","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s00198-009-0893-2","volume":"20","author":"DL Kendler","year":"2009","unstructured":"Kendler DL, Ringe JD, Ste-Marie LG et al (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20(11):1895\u20131902","journal-title":"Osteoporos Int"},{"issue":"9","key":"1791_CR10","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, Van Kuik C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148","journal-title":"J Bone Miner Res"},{"issue":"2","key":"1791_CR11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","volume":"71","author":"JP Brown","year":"2002","unstructured":"Brown JP, Kendler DL, McClung MR et al (2002) The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 71(2):103\u2013111","journal-title":"Calcif Tissue Int"},{"issue":"1","key":"1791_CR12","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne HW, Sorensen O et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11(1):83\u201391","journal-title":"Osteoporos Int"},{"issue":"1","key":"1791_CR13","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","volume":"42","author":"PD Delmas","year":"2008","unstructured":"Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150\u00a0mg once a month in the treatment of postmenopausal osteoporosis. Bone 42(1):36\u201342","journal-title":"Bone"},{"key":"1791_CR14","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003405.pdf . Accessed 18 March 2011"},{"issue":"14","key":"1791_CR15","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"ST Harris","year":"1999","unstructured":"Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282(14):1344\u20131352","journal-title":"JAMA"},{"issue":"5","key":"1791_CR16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, Geusens P, Miller PD et al (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344(5):333\u2013340","journal-title":"N Engl J Med"},{"issue":"8","key":"1791_CR17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","volume":"20","author":"PD Miller","year":"2005","unstructured":"Miller PD, McClung MR, Macovei L et al (2005) Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res 20(8):1315\u20131322","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1791_CR18","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/art.21918","volume":"54","author":"PD Delmas","year":"2006","unstructured":"Delmas PD, Silvano A, Strugala C et al (2006) Intravenous ibandronate injections in postmenopausal women with osteoporosis: one year results from the dosing intravenous administration study. Arthritis Rheum 54(6):1838\u20131846","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"1791_CR19","first-page":"S217","volume":"18","author":"MR McClung","year":"2007","unstructured":"McClung MR, Benhamou C-L, Man Z et al (2007) The efficacy and tolerability of a monthly dosing regimen of 75\u00a0mg risedronate dosed on 2 consecutive days a month for the treatment of postmenopausal osteoporosis-1\u00a0year study results [abstract]. Osteoporos Int 18(Suppl 2):S217\u2013S218","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00198-011-1791-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,7]],"date-time":"2021-12-07T19:02:21Z","timestamp":1638903741000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-011-1791-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["1791"],"URL":"https:\/\/doi.org\/10.1007\/s00198-011-1791-y","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,27]]}}}